Daniel Cejka

2.7k total citations
69 papers, 2.0k citations indexed

About

Daniel Cejka is a scholar working on Nephrology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel Cejka has authored 69 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Nephrology, 16 papers in Molecular Biology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel Cejka's work include Parathyroid Disorders and Treatments (31 papers), Bone health and osteoporosis research (14 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Daniel Cejka is often cited by papers focused on Parathyroid Disorders and Treatments (31 papers), Bone health and osteoporosis research (14 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Daniel Cejka collaborates with scholars based in Austria, United States and Germany. Daniel Cejka's co-authors include Martin Haas, Volker Wacheck, Wolfgang Sieghart, Thorsten Fuereder, Danielle Diarra, Doris Losert, Sabine Strommer, Johannes Werzowa, Katharina Schmid and Markus Peck‐Radosavljevic and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Daniel Cejka

64 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Cejka Austria 24 785 754 516 421 295 69 2.0k
Tetsuro Ishikawa Japan 25 219 0.3× 419 0.6× 763 1.5× 84 0.2× 294 1.0× 136 2.0k
Raquel López‐Mejías Spain 26 113 0.1× 526 0.7× 236 0.5× 51 0.1× 173 0.6× 130 2.0k
Hyun Ju Kim South Korea 16 73 0.1× 299 0.4× 355 0.7× 114 0.3× 76 0.3× 50 1.2k
Claes Juhlin Sweden 24 284 0.4× 212 0.3× 734 1.4× 44 0.1× 115 0.4× 48 2.0k
Shotaro Naito Japan 24 271 0.3× 896 1.2× 547 1.1× 14 0.0× 112 0.4× 82 2.1k
Changgeng Ruan China 32 188 0.2× 856 1.1× 375 0.7× 20 0.0× 226 0.8× 202 3.1k
Andrew W. Minto United States 23 775 1.0× 571 0.8× 217 0.4× 11 0.0× 267 0.9× 36 2.0k
Zuo‐Lin Li China 23 810 1.0× 1.7k 2.3× 64 0.1× 28 0.1× 182 0.6× 70 2.7k
Shushan Yan China 25 134 0.2× 1.2k 1.6× 173 0.3× 45 0.1× 168 0.6× 58 1.9k
Alberto Benito‐Martín Spain 22 365 0.5× 934 1.2× 200 0.4× 14 0.0× 78 0.3× 41 1.7k

Countries citing papers authored by Daniel Cejka

Since Specialization
Citations

This map shows the geographic impact of Daniel Cejka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Cejka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Cejka more than expected).

Fields of papers citing papers by Daniel Cejka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Cejka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Cejka. The network helps show where Daniel Cejka may publish in the future.

Co-authorship network of co-authors of Daniel Cejka

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Cejka. A scholar is included among the top collaborators of Daniel Cejka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Cejka. Daniel Cejka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cejka, Daniel, Mathias Haarhaus, Andreas Pasch, & Edward R. Smith. (2025). Calciprotein Particles and the Mineral Buffering System of Blood. Journal of the American Society of Nephrology. 37(2). 386–389.
2.
Thiem, Ursula, et al.. (2024). The effect of parathyroid hormone lowering by etelcalcetide therapy on calcification propensity and calciprotein particles in hemodialysis patients. Clinical Kidney Journal. 17(6). sfae097–sfae097. 2 indexed citations
3.
Pasch, Andreas, Helmut Lackner, Ilona Papousek, et al.. (2024). Association of serum zinc with mineral stress in chronic kidney disease. Clinical Kidney Journal. 17(9). sfae258–sfae258. 4 indexed citations
4.
5.
Bojić, Marija, Daniel Cejka, Bernhard Bielesz, G. Schernthaner, & Clemens Höbaus. (2023). Secondary calciprotein particle size is associated with patient mortality in peripheral artery disease. Atherosclerosis. 370. 12–17. 4 indexed citations
6.
Antlanger, Marlies, Daniel Cejka, Kathrin Eller, et al.. (2023). Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design. Kidney International Reports. 9(2). 478–481. 3 indexed citations
7.
Sourij, Harald, Friedrich C. Prischl, Susanne Kaser, et al.. (2023). Diabetische Nierenerkrankung (Update 2023). Wiener klinische Wochenschrift. 135(S1). 182–194. 1 indexed citations
8.
Bojić, Marija, Bernhard Bielesz, Daniel Cejka, G. Schernthaner, & Clemens Höbaus. (2021). Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease. Thrombosis and Haemostasis. 122(6). 1040–1046. 5 indexed citations
9.
Odler, Balazs, Martin Windpessl, María Teresinha Arns Steiner, et al.. (2021). The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis. Frontiers in Immunology. 12. 760708–760708. 11 indexed citations
10.
Cejka, Daniel, et al.. (2020). Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report. Transplantation Proceedings. 52(2). 657–659. 8 indexed citations
11.
Bielesz, Bernhard, Thomas Reiter, Rodrig Marculescu, et al.. (2017). Calcification Propensity of Serum is Independent of Excretory Renal Function. Scientific Reports. 7(1). 17941–17941. 18 indexed citations
12.
Bielesz, Bernhard, Janina Patsch, Lukas Fischer, et al.. (2017). Cortical porosity not superior to conventional densitometry in identifying hemodialysis patients with fragility fracture. PLoS ONE. 12(2). e0171873–e0171873. 17 indexed citations
13.
Cejka, Daniel, Rodrig Marculescu, Ina Krämer, et al.. (2016). Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease. Kidney International. 90(4). 828–834. 17 indexed citations
14.
Bielesz, Bernhard, Manfred Hecking, Max Plischke, et al.. (2014). Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients. Clinical Biochemistry. 47(13-14). 1316–1319. 7 indexed citations
15.
Cejka, Daniel & Martin Haas. (2011). Should teriparatide ever be used for adynamic bone disease?. Seminars in Dialysis. 24(4). 431–433. 3 indexed citations
16.
Cejka, Daniel, Michael Weber, Christian Bieglmayer, et al.. (2011). Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrology Dialysis Transplantation. 27(1). 226–230. 121 indexed citations
17.
Cejka, Daniel, Johann Herberth, Adam J. Branscum, et al.. (2010). Sclerostin and Dickkopf-1 in Renal Osteodystrophy. Clinical Journal of the American Society of Nephrology. 6(4). 877–882. 198 indexed citations
18.
Cejka, Daniel, Ying Liu, Matthias Preusser, et al.. (2010). Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biology & Therapy. 9(11). 919–927. 8 indexed citations
19.
Angermayr, Bernhard, Thomas Reiberger, Nataliya Rohr‐Udilova, et al.. (2008). 244 ANGIOGENESIS IN PORTAL HYPERTENSIVE NAD(P)HOXIDASE-KNOCKOUT-MICE IS MEDIATED BY A DIFFERENT PATHWAY THAN IN WILDTYPE ANIMALS. Journal of Hepatology. 48. S99–S99. 1 indexed citations
20.
Wacheck, Volker, Daniel Cejka, Wolfgang Sieghart, et al.. (2006). Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biology & Therapy. 5(10). 1348–1354. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tetsuro Ishikawa Breakdown of academic impact, for papers by Raquel López‐Mejías Breakdown of academic impact, for papers by Hyun Ju Kim Breakdown of academic impact, for papers by Claes Juhlin Breakdown of academic impact, for papers by Shotaro Naito Breakdown of academic impact, for papers by Changgeng Ruan Breakdown of academic impact, for papers by Andrew W. Minto Breakdown of academic impact, for papers by Zuo‐Lin Li Breakdown of academic impact, for papers by Shushan Yan Breakdown of academic impact, for papers by Alberto Benito‐Martín
Rankless by CCL
2026